

# Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.

NCT07125079

---

**Status** RECRUITING  
**Sponsor** University of Pennsylvania  
**Enrollment** 36 participants

## Key Eligibility Criteria

---

### Exclusion (1)

- \-

## Locations (1 total)

---

Hospital Of the University of Pennsylvania, Philadelphia, Pennsylvania, United States